Journal of General Internal Medicine

, Volume 18, Issue 1, pp 57–60

Adverse drug event monitoring at the food and drug administration

Your report can make a difference
Perspectives

Abstract

The Food and Drug Administration (FDA) is responsible not only for approving drugs but also for monitoring their safety after they reach the market. The complete adverse event profile of a drug is not known at the time of approval because of the small sample size, short duration, and limited generalizability of pre-approval clinical trials. This report describes the FDA’s postmarketing surveillance system, to which many clinicians submit reports of adverse drug events encountered while treating their patients. Despite its limitations, the spontaneous reporting system is an extremely valuable mechanism by which hazards with drugs that were not observed or recognized at the time of approval are identified. Physicians are strongly encouraged to submit reports of adverse outcomes with suspect drugs to the FDA, and their reports make a difference. The FDA is strengthening its postmarketing surveillance with access to new data sources that have the potential to further improve the identification, quantification, and subsequent management of drug risk.

Key words

Food and Drug Administration (FDA) adverse drug events postmarketing surveillance MedWatch drug withdrawals 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. In: Strom BL, ed. Pharmacoepidemiology, 3rd ed. Chichester: John Wiley and Sons, Ltd.; 2000:151–74.Google Scholar
  2. 2.
    Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA. 1993;269:2765–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Ahmad SR. MEDWatch. Lancet. 1993;341:1465.Google Scholar
  5. 5.
    Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med. 1995;155:1949–56.PubMedCrossRefGoogle Scholar
  6. 6.
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reaction in hospitalized patients. JAMA. 1998;279:1200–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Scott HD, Rosenbaum SE, Waters WJ, et al. Rhode Island physicians’ recognition and reporting of adverse drug reactions. R I Med J. 1987;70:311–16.PubMedGoogle Scholar
  9. 9.
    Rogers AS, Israel E, Smith CR. Physician knowledge, attitudes, and behavior related to reporting adverse drug events. Arch Intern Med. 1988;148:1589–92.CrossRefGoogle Scholar
  10. 10.
    Lindquist M, Edwards IR. The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol. 2001;28:1180–7.PubMedGoogle Scholar
  11. 11.
    Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001;286:831–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA. 2000;284:3036–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol. 2001;45:515–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357:1766–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol. 2001;96:1698–703.PubMedCrossRefGoogle Scholar
  16. 16.
    LaGrenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med. 2001;345:224–5.CrossRefGoogle Scholar
  17. 17.
    Brinker A, Beitz J. Spontaneous reports of pulmonary embolism in association with raloxifene. Obstet Gynecol. 2001;98:1151.PubMedCrossRefGoogle Scholar
  18. 18.
    Weaver J, Bonnel RA, Karwoski CB, Brinker AD, Beitz J. GI events leading to death in association with celecoxib and rofecoxib. Am J Gastroenterol. 2001;96:3449–50.PubMedGoogle Scholar
  19. 19.
    LaGrenade L, Graham DJ, Nourjah P. Underreporting of hemorrhagic stroke associated with phenylpropanolamine. JAMA. 2001;286:3081.CrossRefGoogle Scholar
  20. 20.
    Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Aseptic meningitis associated with rofecoxib. Arch Intern Med. 2002;162:713–15.PubMedCrossRefGoogle Scholar
  22. 22.
    Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol. 2002;89:1331–34.PubMedCrossRefGoogle Scholar
  23. 23.
    Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med. 2002;346:1832–3.PubMedCrossRefGoogle Scholar
  24. 24.
    Bonnel RA, Villaba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med. 2002;22:385–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Ahmad SR, Kortepter C, Brinker A, Chen M, Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25:537–44.PubMedCrossRefGoogle Scholar
  26. 26.
    Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis. 2002;35:197–200.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2003

Authors and Affiliations

  1. 1.Center for Drug Evaluation and Research HFD-430Ahmad: Division of Drug Risk Evaluation, Office of Drug Safety, Food and Drug AdministrationRockville

Personalised recommendations